Trial shows Eliquis reduces hospitalisation in DVT - BMS/Pfizer

Bristol-Myers Squibb and Pfizer have announced results of a pre-specified secondary analysis of the Eliquis (Apixaban) Phase III AMPLIFY-EXT trial for Pulmonary Embolism and Deep Vein Thrombosis. The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Of the 2,486 patients included in the AMPLIFY-EXT trial, 138 patients were hospitalized at least once, including 62 (7.48%) in the placebo group (n=829), 42 (5.00%) in the Eliquis 2.5 mg group (n=840), and 34 (4.18%) in the Eliquis 5 mg group (n=813).

Of the first hospitalizations in the placebo group, a total of 32 (51.6%) were attributed to VTE recurrence versus six (17.7%) in the Eliquis 5 mg group and 11 (26.2%) in the Eliquis 2.5 mg group. Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo. This effect was independent of other variables including renal function, the only other significant predictor of hospitalization in the AMPLIFY-EXT .population. These data were presented during an oral session in Barcelona, Spain, at the ESC Congress 2014.